Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04649385 · ClinicalTrials.gov registry record · Phase 1

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by BeiGene.

Active
Registry status
Phase 1
Development phase
157
Enrollment target
20
Study locations

NCT04649385 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 157 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04649385, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by BeiGene.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
157 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Tislelizumab
  • DRUG BGB-15025

Study Locations (20)

Seoul Teugbyeolsi

  • Samsung Medical Center - GangnamGu
  • The Catholic University of Korea, Seoul St Marys Hospital - SeochoGu
  • Severance Hospital Yonsei University Health System - SeodaemunGu
  • Asan Medical Center - SongpaGu

Texas

  • The University of Texas Md Anderson Cancer Center - Houston
  • Ut Health San Antonio Mays Cancer Center - San Antonio

Henan

  • Henan Cancer Hospital - Zhengzhou
  • The First Affiliated Hospital of Zhengzhou University - Zhengzhou

New York

  • Icahn School of Medicine At Mount Sinai - New York

New South Wales

  • Prince of Wales Hospital - Randwick

South Australia

  • Ashford Cancer Centre Research Northeast - Windsor Gardens

Victoria

  • Peter Maccallum Cancer Centre - Melbourne

Western Australia

  • Linear Clinical Research - Nedlands

Trial Details

FieldValue
Enrollment Target 157 participants
Start Date 2021-03-04
Est. Completion 2026-05-16
Phase Phase 1

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04649385

The ClinicalTrials.gov registry entry for NCT04649385 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (18% lower). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Tislelizumab is the first listed.

NCT04649385 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Seoul Teugbyeolsi, Texas, Henan.

Frequently Asked Questions

What is clinical trial NCT04649385 about?

NCT04649385 is a clinical study titled "BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors". The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with t...

What is the current status of trial NCT04649385?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 157 participants. The study started on 2021-03-04. Estimated completion is 2026-05-16.

What conditions does trial NCT04649385 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT04649385?

The interventions under investigation include: Tislelizumab (DRUG), BGB-15025 (DRUG).

Who is sponsoring clinical trial NCT04649385?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04649385 being conducted?

This trial has 20 study locations across New York, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.